News
The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...
4d
Axios on MSNVinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
The United States Food and Drug Administration has chosen Dr Vinay Prasad to lead its Center for Biologics Evaluation and Research.
3dOpinion
MedPage Today on MSNVinay Prasad Speaks to CBER Staff: Which Prasad Showed Up?The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...
In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
Not Vinay Prasad. The new top regulator of vaccines and gene therapies at the Food and Drug Administration has never shied ...
Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was ...
The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
FDA Commissioner Marty Makary named Vinay Prasad, a hematologist oncologist and critic of the Covid-19 vaccine for children, ...
The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA leadership and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results